Akebia Therapeutics (NASDAQ:AKBA) will release its quarterly earnings report on Thursday, 2026-02-26. Here’s a brief overview for investors ahead of the announcement.
Analysts anticipate Akebia Therapeutics to report an earnings per share (EPS) of $-0.05.
Investors in Akebia Therapeutics are eagerly awaiting the company’s announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It’s worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
Past Earnings Performance
During the last quarter, the company reported an EPS beat by $0.02, leading to a 8.38% increase in the share price on the subsequent day.
Here’s a look at Akebia Therapeutics’s past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.02 | -0.02 | -0.04 | -0.08 |
| EPS Actual | 0.00 | 0.00 | 0.03 | -0.10 |
| Price Change % | 8.38 | 13.62 | -2.67 | 33.73 |
Market Performance of Akebia Therapeutics’s Stock
Shares of Akebia Therapeutics were trading at $1.24 as of February 24. Over the last 52-week period, shares are down 32.24%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.